Artelo Biosciences (NASDAQ:ARTL) Announces Quarterly Earnings Results

Artelo Biosciences (NASDAQ:ARTL) posted its earnings results on Tuesday. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.10, Yahoo Finance reports.

Artelo Biosciences Price Performance

Artelo Biosciences stock traded down $0.03 during mid-day trading on Wednesday, hitting $1.27. The company’s stock had a trading volume of 5,900 shares, compared to its average volume of 42,693. Artelo Biosciences has a 52-week low of $1.15 and a 52-week high of $2.98. The company has a market cap of $4.10 million, a PE ratio of -0.41 and a beta of 1.43. The firm’s 50 day moving average is $1.33 and its 200 day moving average is $1.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a research note on Wednesday.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.